Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

An Assessment of Five (PANSS, SAPS, SANS, NSA-16, CGI-SCH) commonly used Symptoms Rating Scales in Schizophrenia and Comparison to Newer Scales (CAINS, BNSS).

Kumari S, Malik M, Florival C, Manalai P, Sonje S.

J Addict Res Ther. 2017;8(3). pii: 324. doi: 10.4172/2155-6105.1000324. Epub 2017 May 11.

2.

Psychometric validation of a multi-dimensional capability instrument for outcome measurement in mental health research (OxCAP-MH).

Vergunst F, Jenkinson C, Burns T, Anand P, Gray A, Rugkåsa J, Simon J.

Health Qual Life Outcomes. 2017 Dec 28;15(1):250. doi: 10.1186/s12955-017-0825-3.

3.

Estimation of Symptom Severity Scores for Patients with Schizophrenia Using ERP Source Activations during a Facial Affect Discrimination Task.

Kim DW, Lee SH, Shim M, Im CH.

Front Neurosci. 2017 Aug 3;11:436. doi: 10.3389/fnins.2017.00436. eCollection 2017.

4.

Treatment outcomes in schizophrenia: qualitative study of the views of family carers.

Lloyd J, Lloyd H, Fitzpatrick R, Peters M.

BMC Psychiatry. 2017 Jul 21;17(1):266. doi: 10.1186/s12888-017-1418-8.

5.

Transdiagnostic Clinical Global Impression Scoring for Routine Clinical Settings.

Dunlop BW, Gray J, Rapaport MH.

Behav Sci (Basel). 2017 Jun 27;7(3). pii: E40. doi: 10.3390/bs7030040.

6.

The role of life context and self-defined well-being in the outcomes that matter to people with a diagnosis of schizophrenia.

Lloyd H, Lloyd J, Fitzpatrick R, Peters M.

Health Expect. 2017 Oct;20(5):1061-1072. doi: 10.1111/hex.12548. Epub 2017 Apr 3.

7.

Clinician-Reported Outcome Assessments of Treatment Benefit: Report of the ISPOR Clinical Outcome Assessment Emerging Good Practices Task Force.

Powers JH 3rd, Patrick DL, Walton MK, Marquis P, Cano S, Hobart J, Isaac M, Vamvakas S, Slagle A, Molsen E, Burke LB.

Value Health. 2017 Jan;20(1):2-14. doi: 10.1016/j.jval.2016.11.005. Epub 2017 Jan 10.

8.

Iloperidone in the treatment of schizophrenia: an evidence-based review of its place in therapy.

Tonin FS, Wiens A, Fernandez-Llimos F, Pontarolo R.

Core Evid. 2016 Dec 14;11:49-61. doi: 10.2147/CE.S114094. eCollection 2016. Review.

9.

The Use of the Health of the Nation Outcome Scales for Assessing Functional Change in Treatment Outcome Monitoring of Patients with Chronic Schizophrenia.

Egger ST, Vetter S, Weniger G, Vandeleur C, Seifritz E, Müller M.

Front Public Health. 2016 Oct 13;4:220. eCollection 2016.

10.

Community-based Rehabilitation Intervention for people with Schizophrenia in Ethiopia (RISE): study protocol for a cluster randomised controlled trial.

Asher L, De Silva M, Hanlon C, Weiss HA, Birhane R, Ejigu DA, Medhin G, Patel V, Fekadu A.

Trials. 2016 Jun 24;17(1):299. doi: 10.1186/s13063-016-1427-9.

11.

Lay health supporters aided by a mobile phone messaging system to improve care of villagers with schizophrenia in Liuyang, China: protocol for a randomised control trial.

Xu DR, Gong W, Caine ED, Xiao S, Hughes JP, Ng M, Simoni J, He H, Smith KL, Brown HS 3rd, Gloyd S.

BMJ Open. 2016 Jan 20;6(1):e010120. doi: 10.1136/bmjopen-2015-010120.

12.

Cardiac Coherence Training to Reduce Anxiety in Remitted Schizophrenia, a Pilot Study.

Trousselard M, Canini F, Claverie D, Cungi C, Putois B, Franck N.

Appl Psychophysiol Biofeedback. 2016 Mar;41(1):61-9. doi: 10.1007/s10484-015-9312-y.

13.

The social functional outcome of being naturalistically treated with paliperidone extended-release in patients with schizophrenia.

Nakagawa R, Ohnishi T, Kobayashi H, Wakamatsu A, Tanimura A, Morita K, Yamaoka T, Usui H, Ogawa Y, Fujino A, Yoshizawa K.

Neuropsychiatr Dis Treat. 2015 Jun 22;11:1511-21. doi: 10.2147/NDT.S85891. eCollection 2015.

14.

Thyroid axis function after in-patient treatment of acute psychosis with antipsychotics: a naturalistic study.

Bunevicius R, Steibliene V, Prange AJ Jr.

BMC Psychiatry. 2014 Oct 8;14:279. doi: 10.1186/s12888-014-0279-7.

15.

Converting positive and negative symptom scores between PANSS and SAPS/SANS.

van Erp TG, Preda A, Nguyen D, Faziola L, Turner J, Bustillo J, Belger A, Lim KO, McEwen S, Voyvodic J, Mathalon DH, Ford J, Potkin SG, Fbirn.

Schizophr Res. 2014 Jan;152(1):289-94. doi: 10.1016/j.schres.2013.11.013. Epub 2013 Dec 11.

16.

Adjuvant therapy with minocycline for schizophrenia (The MINOS Trial): study protocol for a double-blind randomized placebo-controlled trial.

Fekadu A, Mesfin M, Medhin G, Alem A, Teferra S, Gebre-Eyesus T, Seboxa T, Assefa A, Hussein J, Lemma MT, Borba C, Henderson DC, Hanlon C, Shibre T.

Trials. 2013 Nov 27;14:406. doi: 10.1186/1745-6215-14-406.

17.

Effects of smoking abstinence on cigarette craving, nicotine withdrawal, and nicotine reinforcement in smokers with and without schizophrenia.

Tidey JW, Colby SM, Xavier EM.

Nicotine Tob Res. 2014 Mar;16(3):326-34. doi: 10.1093/ntr/ntt152. Epub 2013 Oct 10.

18.

Nicotinic modulation of intrinsic brain networks in schizophrenia.

Smucny J, Tregellas J.

Biochem Pharmacol. 2013 Oct 15;86(8):1163-72. doi: 10.1016/j.bcp.2013.06.011. Epub 2013 Jun 21. Review.

19.

Disability and schizophrenia: a systematic review of experienced psychosocial difficulties.

Świtaj P, Anczewska M, Chrostek A, Sabariego C, Cieza A, Bickenbach J, Chatterji S.

BMC Psychiatry. 2012 Nov 9;12:193. doi: 10.1186/1471-244X-12-193. Review.

20.

Naturalistic outcome of treatment of psychosis by traditional healers in Jinja and Iganga districts, Eastern Uganda - a 3- and 6 months follow up.

Abbo C, Okello ES, Musisi S, Waako P, Ekblad S.

Int J Ment Health Syst. 2012 Sep 8;6(1):13. doi: 10.1186/1752-4458-6-13.

Supplemental Content

Support Center